ADMA Biologics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated October 10, 2017, details ADMA Biologics, Inc.'s entry into a new senior secured term loan facility. The filing reports the closing of a Credit Agreement with Marathon Healthcare Finance Fund, L.P., replacing a prior credit facility with Oxford Finance LLC.
Key Financial Metrics and Debt Structure
- Total Facility Size: Up to $40.0 million.
- Tranche One Loan: $30.0 million funded on the Closing Date.
- Tranche Two Loan: Up to $10.0 million, subject to specific FDA and revenue conditions.
- Interest Rate: LIBOR plus 9.50% (with a 1% LIBOR floor). This may decrease to LIBOR plus 7.75% if 2018 sales reach $61.7 million and Tranche Two is funded.
- Deferred Facility Fee: 9.20% of the funded amount, payable at maturity.
- Maturity Date: April 10, 2022.
- Amortization: Principal payments commence October 10, 2020, over an 18-month schedule. Interest-only payments apply prior to this date.
- Liquidity Covenant: Borrower must maintain at least $5.5 million in a Debt Service Reserve Account.
Material Changes and Use of Proceeds
The Company used the $30.0 million Tranche One proceeds as follows:
- $17.0 million: To retire and pay in full the existing credit facility with Oxford Finance LLC.
- $5.5 million: To pre-fund the required Debt Service Reserve Account.
- $1.5 million: To pay diligence fees, legal, and other transaction expenses.
- ~$6.0 million: Allocated for remediation of FDA issues (Complete Response Letter and warning letter) and general corporate purposes.
The filing also notes the termination of the prior Oxford Loan and Security Agreement, which was superseded by the new Credit Agreement.
Conditions, Risks, and Unusual Items
- Tranche Two Conditions: Funding is contingent on FDA validation/approval of Bivigam or RI-002 and the generation of at least $500,000 in net revenue from these products in 2018 or 2019, respectively.
- Equity Issuance: The Company issued a warrant to purchase 338,710 shares of common stock (3.5% of the Tranche One Loan) with an exercise price of $3.10 and an expiration date of October 10, 2024. A similar warrant is issuable upon funding of Tranche Two.
- Collateral: The loan is secured by a first-priority lien on substantially all Company assets, including a mortgage on the Boca Raton, Florida facility, and all intellectual property rights.
- Prepayment Penalties: Significant prepayment premiums apply, including a "Make-Whole Amount" if prepaid within the first three years, and declining premiums (3%, 2%, 1%) thereafter.
- Default Risk: An Event of Default triggers an interest rate increase of 5% per annum and potential acceleration of the entire debt.
Investor Verification Checklist
- Verify the current status of FDA remediation efforts for Bivigam and RI-002 to assess the likelihood of Tranche Two funding.
- Confirm the Company's ability to maintain the $5.5 million liquidity covenant given the high interest rate and deferred fees.
- Review the dilution impact of the issued warrants (3.5% of loan value) on existing shareholders.
- Assess the impact of the 9.20% deferred facility fee on the Company's cash flow at maturity in 2022.
- Monitor the Company's revenue trajectory against the $61.7 million threshold required to reduce the interest rate.